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EDITORIAL

Radiomics – Using Artificial Intelligence in the Quest towards
Personalised Radiation Treatment
Ahmed Nadeem Abbasi, Agha Muhammad Hammad Khan and Bilal Mazhar Qureshi
The term radiomics is a newer concept evolved over the
past two decades. Imaging data is stored in a data-base
that can be utilised in order to process and review
variations in treatment outcomes.1 Artificial intelligence
(AI) and Big Data is evolving with practical implementation in a number of areas in the healthcare
systems resulting in improvement of patient care and
medical related outcomes.2 The future trend is steering
towards dependency on encrypted digitalised data
storage. Out of these data, one is related to diagnostic
radiology which includes information in the form of
radiographs, ultrasound scans, mammograms, CT
scans, MRIs, and metabolic imaging such as PET/CT
scan that may have a potential to address multiple
oncology related queries by improving diagnostic,
prognostic, and predictive accuracy of cancer
management. Treatment related response can be
validated in such a way that it can be further adapted
with the concept of 'personalised' treatment in radiation
oncology.3
Imaging, being a non-invasive procedure, is being used
during multiple phases of a patient's treatment journey.
Imaging is done for diagnosis, staging, radiation
planning, and response assessments; giving us an edge
of tracking the tumor from the beginning till end. It allows
a clinician to visualise a tumor through all these phases.
Treatment has evolved from gray scales algorithms to
fusion of images and then to functional imaging, leading
to modification of treatment plans.4
Summation of existing data is a real challenge due to
heterogeneity in protocol used at different institutions.
Limitations arise when we review the literature, which
show that there is no standardisation of definition of
imaging data. Most of the studies used their in-house
developed software, which was not shared in masses,
making it an exclusive thing that is challenging its
potential of changing the dynamics of future of oncology
treatment. A number of variations do exist while
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acquiring data, which includes noise corrections,
difference in vendor setting for every equipment,
dynamic changes in the form of progression, and
shrinkage of tumors and organ motion. These variations
can be managed by using appropriate maneuvers. A
four-step model has taken into account for processing all
the radiological data. Lambin et al. described this flow
and identified the steps. These include imaging,
segmentation, feature extraction, and analysis. First
step is identifying imaging data to start the process
followed by software-based automated segmentation of
structures to avoid intra- and inter-subjective variability,
leading to feature extraction. Taking an example of CT
imaging, the most common imaging modality used in
oncology practice: identified intensity, textures, wavelet
and shape features can be used to evaluate temporal
relation with genetics and survival models. The final step
is analysis by a radiomic software that will predict model
and validation by making use of statistic models.5
Many studies have been conducted in order to identify
radiological association with genomic, cellular,
molecular, metabolic, and clinical data. More the data is
combined, greater are the chances of identifying statistic
proven relation with radiological data.6 Stephen et al.
reported genotype-phenotype interaction between FDGPET and EGFR mutations, enlightening the use of noninvasive imaging as a tool to predict a mutation in nonsmall cell lung cancer.7 A study conducted on a cohort of
110 patients with grade II glioma tumors showed
association of IDH1 mutation with T2-Flair images with
area under the ROC (receiver-operating characteristic)
curve to 0.86.8 Similar results were concluded from a
glioblastoma-based study, where radiological data was
extracted with 12-month survival rate and EGFR mutation.9
Parmer et al. identified multiple radiomic clusters with
patient survival and staging in head and neck and
lung cancers with significant p-value (Lung RS = 0.92,
p <0.001, H&N RS = 0.92, p <0.001). Moreover, on
multivariate analysis radiomic features were also
related to predictive models.10 Radiomic features can be
correlated with gene expression, mutation, histopathological grading, hormone status, micro-vascular
density, tumor metabolism, and malignancy predicItion.
At this moment, it is very difficult for a radiation oncologist
to confess that radiomic data, on its own, can influence
and/or alter patient's radiation treatment. As discussed
previously, it is imperative to utilise other data sets as
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well, including clinical, genomics, and proteomics. Aerts
et al. computed that if all the data are merged and
processed, its power of predicting the development of an
association can be enhanced; and it can give more
power to a study. The greater the cohorts for
comparisons with radiological data, the better the
chances for implementation and further evolution for
personalised treatment in the area of oncology.6
The concept of the recently proposed virtual biopsy will
challenge the current model of oncologic management;
which has a pathway of imaging, followed by surgical
resection. A single-point tissue biopsy may decide the
whole treatment process, ignoring the tissue heterogeneity that may not only exist within the tumor
specimen but also missing heterogeneity that may exist
in other distant parts of the body. With the help of
radiomics, these virtual biopsies will have a pathway of
radiomic assessment without tissue extraction. Multiple
sites can be evaluated with a non-invasive technique,
giving chance to determine and alter treatment which is
not based on single-tissue specimen. Hence, the
heterogeneity that current model cannot pick up due to
its practical limitations.11
The whole concept spins around developing and
consolidating personalised oncology practice, where
each and every patient should be treated as per his or
her need to prolong overall survival and minimising
toxicities. Hence, improving therapeutic ratio. This notion
explains that no two individuals are alike, which will
challenge the current concept of making cohorts and
treating them on same pattern because outcomes do
vary due to heterogeneity in tumors because of genetic
configuration. Developments of CDSS (clinical decision
support system) will analyse radiological data to help
healthcare providers make decisions and improve
patient care.12 Many radiation oncologists believe that
personalised radiation treatment is the future of radiation
oncology; and radiomics will become the new face of
radiation therapy in the upcoming years. The jury is still
out, we must confess that the data is emerging; and at
this moment, it is not fully mature. Advent of concepts of
radiomics offers a potential opportunity towards positive
changes in the understanding of radiation oncology.
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